Display Settings:

Format

Send to:

Choose Destination
    Dermatol Online J. 2008 Sep 15;14(9):12.

    Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.

    Abstract

    Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-alpha). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, new-onset psoriasis in a patient on infliximab for rheumatoid arthritis.

    PMID:
    19061594
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for Arthur C Huntley MD, California Digital Library

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk